

Hedwig M Blommestein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5194047/publications.pdf>

Version: 2024-02-01

25
papers

311
citations

840776

11
h-index

888059

17
g-index

25
all docs

25
docs citations

25
times ranked

617
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach. <i>Health Economics (United Kingdom)</i> , 2022, 31, 135-156. | 1.7 | 2 |
| 2 | Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. <i>Cancers</i> , 2022, 14, 2444. | 3.7 | 2 |
| 3 | A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. <i>Leukemia and Lymphoma</i> , 2021, 62, 549-559. | 1.3 | 5 |
| 4 | Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e62. | 0.5 | 14 |
| 5 | Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497. | 5.9 | 7 |
| 6 | Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. <i>Medical Decision Making</i> , 2021, 41, 439-452. | 2.4 | 21 |
| 7 | Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. <i>Melanoma Research</i> , 2021, 31, 249-257. | 1.2 | 1 |
| 8 | Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-12. | 2.4 | 1 |
| 9 | A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 5606. | 3.7 | 5 |
| 10 | Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28588. | 1.5 | 5 |
| 11 | Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. <i>Value in Health</i> , 2020, 23, 1497-1508. | 0.3 | 1 |
| 12 | Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 825-831. | 1.0 | 17 |
| 13 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035. | 3.5 | 17 |
| 14 | Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. <i>European Journal of Haematology</i> , 2018, 101, 676-683. | 2.2 | 4 |
| 15 | Long-term Outcomes in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e45. | 2.7 | 38 |
| 16 | Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. <i>Value in Health</i> , 2017, 20, 627-636. | 0.3 | 27 |
| 17 | Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. <i>Clinical Therapeutics</i> , 2017, 39, 1221-1232.e4. | 2.5 | 17 |
| 18 | Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1211-1221. | 3.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. <i>European Journal of Haematology</i> , 2016, 96, 198-208. | 2.2 | 33 |
| 20 | Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. <i>Leukemia Research</i> , 2016, 50, 37-45. | 0.8 | 12 |
| 21 | Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2109-2110. | 2.0 | 2 |
| 22 | Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. <i>Pharmacoeconomics</i> , 2016, 34, 23-31. | 3.3 | 2 |
| 23 | A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. <i>Pharmacoeconomics</i> , 2015, 33, 551-560. | 3.3 | 30 |
| 24 | Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. <i>European Journal of Haematology</i> , 2014, 92, 398-406. | 2.2 | 16 |
| 25 | Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. <i>Value in Health</i> , 2014, 17, 245-253. | 0.3 | 11 |